Kindstar Globalgene Technology (Kindstar Globalgene Technology) Cash-to-Debt : 10.42 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Kindstar Globalgene Technology Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Kindstar Globalgene Technology's cash to debt ratio for the quarter that ended in Dec. 2023 was 10.42.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Kindstar Globalgene Technology could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Kindstar Globalgene Technology's Cash-to-Debt or its related term are showing as below:

KDGTF' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.25 Med: 10.22 Max: 117.92
Current: 10.42

During the past 6 years, Kindstar Globalgene Technology's highest Cash to Debt Ratio was 117.92. The lowest was 0.25. And the median was 10.22.

KDGTF's Cash-to-Debt is ranked better than
78.76% of 226 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.285 vs KDGTF: 10.42

Kindstar Globalgene Technology Cash-to-Debt Historical Data

The historical data trend for Kindstar Globalgene Technology's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Kindstar Globalgene Technology Cash-to-Debt Chart

Kindstar Globalgene Technology Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

0.26

11.20

117.89

10.01

10.42

Kindstar Globalgene Technology Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial					117.89	97.95	10.01	9.13	10.42

Competitive Comparison of Kindstar Globalgene Technology's Cash-to-Debt

For the Diagnostics & Research subindustry, Kindstar Globalgene Technology's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kindstar Globalgene Technology's Cash-to-Debt Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Kindstar Globalgene Technology's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Kindstar Globalgene Technology's Cash-to-Debt falls into.

Kindstar Globalgene Technology Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Kindstar Globalgene Technology's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	283.64	/	(23.113	+	4.097)
	=	10.42

Kindstar Globalgene Technology's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	283.64	/	(23.113	+	4.097)
	=	10.42

Kindstar Globalgene Technology (OTCPK:KDGTF) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Kindstar Globalgene Technology Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Kindstar Globalgene Technology's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Kindstar Globalgene Technology (Kindstar Globalgene Technology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Kindstar Globalgene Technology Inc (OTCPK:KDGTF) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

09960:Hong Kong

Address

Biolake D2-1, 666 Gaoxin Road, East Lake High Tech Zone, Hubei Province, Wuhan, CHN

Website

https://www.kindstar.com.cn

Kindstar Globalgene Technology Inc is principally engaged in the provision of clinical testing services. It organizes the business into nine segments, including hematology testing, genetic disease and rare disease testing, infectious disease testing, oncology testing, neurology testing, maternity-related testing, COVID-19-related testing, routine testing, and Other segment provides Testing services for R&D projects and others and miscellaneous services.

Kindstar Globalgene Technology (Kindstar Globalgene Technology) Headlines

No Headlines